First patient dosed with ADC therapy designed to disrupt tumor blood supply

CAR-T Digest - August 2020

13 Aug 2024: First patient dosed with ADC therapy designed to disrupt tumor blood supply

Angiex has initiated the first-in-human trial of AGX101, an antibody-drug conjugate (ADC) designed to target solid tumors
AGX101 works by starving tumors of blood supply and inhibiting their spread
The drug targets TM4SF1, a protein involved in tumor angiogenesis and metastasis
Preclinical studies showed increased survival and tumor shrinkage
The primary goal of the phase 1 trial is to assess the safety and tolerability of AGX101 while obtaining preliminary efficacy data